Response Letter to "Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China"

被引：0
|
作者：
Guan, Haijing [1 ]
Sheng, Yanan [2 ]
Guo, Wanjie [3 ]
Han, Sheng [3 ]
Shi, Luwen [1 ]
机构：
[1] Peking Univ, Sch Pharmaceut Sci, Beijing, Peoples R China
[2] Peking Univ, China Ctr Hlth Econ Res, Beijing, Peoples R China
[3] Peking Univ, Int Res Ctr Med Adm, Beijing, Peoples R China
来源：
ADVANCES IN THERAPY | 2020年 / 37卷 / 02期
关键词：
Alectinib; ALK; China; Cost-Effectiveness; NSCLC; CRIZOTINIB;
D O I：
10.1007/s12325-019-01202-2
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：971 / 972
页数：2
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF ALECTINIB VERSUS CRIZOTINIB IN FIRST LINE ALK-POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Stefani, S. D.
    Santos, M.
    Kashiura, D.
    Leme-Souza, R.
    Fahham, L.
    VALUE IN HEALTH, 2019, 22 : S478 - S479
  • [32] Treatment of ALK-Positive Non-Small Cell Lung Cancer
    Bang, Yung-Jue
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2012, 136 (10) : 1201 - 1204
  • [33] Treating ALK-positive non-small cell lung cancer
    Ziogas, Dimitrios C.
    Tsiara, Anna
    Tsironis, Georgios
    Lykka, Maria
    Liontos, Michalis
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
  • [34] Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
    Yu, Hui
    Sun, Si
    Hu, Xingjiang
    Xia, Jinjing
    Wang, Jialei
    Chen, Haiquan
    ONCOTARGETS AND THERAPY, 2019, 12 : 6481 - 6495
  • [35] The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer
    Kaczmar, John
    Mehra, Ranee
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (05) : 236 - 241
  • [36] Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
    Hu, Yan
    Ren, Siying
    Wang, Ruoyao
    Han, Wei
    Xiao, Peng
    Wang, Li
    Yu, Fenglei
    Liu, Wenliang
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [37] Phase II Trial of the Combination of Alectinib with Bevacizumab in ALK-Positive Nonsquamous Non-Small Cell Lung Cancer
    Watanabe, S.
    Matsumoto, N.
    Koshio, J.
    Ishida, A.
    Tanaka, T.
    Abe, T.
    Ishikawa, D.
    Shoji, S.
    Nozaki, K.
    Ichikawa, K.
    Kondo, R.
    Otsubo, A.
    Aoki, A.
    Kajiwara, T.
    Koyama, K.
    Miura, S.
    Yoshizawa, H.
    Kikuchi, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S336 - S336
  • [38] Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
    Karachaliou, Niki
    Fernandez Bruno, Manuel
    Paulina Bracht, Jillian Wilhelmina
    Rosell, Rafael
    ONCOTARGETS AND THERAPY, 2019, 12 : 4567 - 4575
  • [39] How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
    Takigawa, Nagio
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : 1438 - 1440
  • [40] Predictors of treatment response in ALK-positive metastatic non-small cell lung cancer
    Dogan, I.
    Gurbuz, M.
    Paksoy, N.
    Ferhatoglu, F.
    Vatansever, S.
    Saip, P.
    Demirkazik, A.
    Aydiner, A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S782 - S782
12345